Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer

Clinical and Experimental Medicine

Volumn 14, Issue 1, 2014, Pages 107-113

  Krześlak, Anna ^a   Forma, Ewa ^a   Jóźwiak, Paweł ^a   Szymczyk, Agnieszka ^a   Smolarz, Beata ^b   Romanowicz Makowska, Hanna ^b   Rózański, Waldemar ^c   Bryś, Magdalena ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; Metallothionein 2A; SNP

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; LIFE STYLE; METALLOTHIONEIN; MIDDLE AGED; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 84895197966     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-012-0215-4     Document Type: Article

References (28)

1. Coyle P, Philcox JC, Carey LC, Rofe AM (2002) Metallothionein: the multipurpose protein. Cell Mol Sci 59:627-647
2. Thirumoorthy N, Manisenthil Kumar KT, Shyam Sunder A, Panayappan L, Chatterjee M (2007) Metallothionei: an overview. World J Gastroenerol 13:993-996
3. Thirumoorthy N, Shyam Sunder A, Manisenthil Kumar K, Senthil Kumar M, Ganesh G, Chatterjee M (2011) A review of metallothionein isoforms and their role in pathophysiology. World J Surg Oncol 9:54. doi: 10.1186/1477-7819-9-54
4. Sabolić I, Breljak D, Skarica M, Herak-Kramberger CM (2010) Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs. Biometals 23:897-926
5. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M (2009) The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44:29-64
6. Namdarghanbari M, Wobig W, Krezoski S, Tabatabai NM, Petering DH (2011) Mammalian metallothionein in toxicology, cancer, and cancer chemotherapy. J Biol Inorg Chem 16:1087-1101
7. Cherian MG, Jayasurya A, Bay BH (2003) Metallothionein in human tumors and potential roles in carcinogenesis. Mutat Res 533:201-209
8. Haq F, Mahoiney M, Kropatnicki J (2003) Signaling events for metallothionein induction. Mutat Res 533:211-226
9. Theocharis SE, Margeli AP, Kilijanienko JT, Kouraklis GP (2004) Metallothionein expression in human neoplasia. Histopthology 45:103-118
10. Dziegiel P (2004) Expression of metallothionein in human cells. Pol J Pathol 55:3-12
11. Jin R, Huang J, Tan P, Bay B (2004) Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res 10:74-79
12. Bay BH, Jin R, Huang J, Tan PH (2006) Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med (Maywood) 231:1516-1521
13. Kita K, Miura M, Yoshida M et al (2006) Potential effect on cellular response to cadmium of a single-nucleotide A→G polymorphism in the promoter of the human gene for metallothionein IIA. Hum Genet 120:553-560
14. Giacconi R, Cipriano C, Muti E et al (2005) Novel -209A/G MT2A polymorphism in old patients with type 2 diabetes and atherosclerosis: relationship with inflammation (IL-6) and zinc. Biogerontology 6:407-413
15. Giacconi R, Muti E, Malavolta M et al (2007) The +838 C/G MT2A polymorphism, metals, and the inflammatory/immune response in carotid artery stenosis in elderly people. Mol Med 13:388-395
16. Kayaalti Z, Söylemezoglu T (2010) The polymorphism of core promoter region om metallothionein 2A-metal binding protein in Turkish population. Mol Biol Rep 37:185-190
17. McElroy JA, Bryda EC, McKay SD, Schnabel RD, Taylor JF (2010) Genetic variation at a metallothionein 2A promoter single-nucleotide polymorphism in white and black females in Midwestern United States. J Toxicol Environ Health A 73:1283-1287
18. KayaaltI Z, Aliyev V, Söylemezoǧlu T (2011) The potential effect of metallothionein 2A-5A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. Toxicol Appl Pharmacol 256:1-7
19. Kayaalti Z, Mergen G, Söylemezoǧlu T (2011) Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. Toxicol Appl Pharmacol 245:252-255
20. Tekin D, KayaaltI Z, Söylemezoǧlu T (2012) The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels. Int Arch Occup Environ Health 85:631-637
21. Yang L, Li H, Yu T et al (2008) Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am J Physiol Endocrinol Metab 294:E987-E992
22. Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH (2002) Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23:81-86
23. Abdel-Mageed A, Agrawal KC (1997) Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 4:199-207
24. Lim D, Jocelyn KM, Yip GW, Bay BH (2009) Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett 276:109-117
25. Cai L, Klein JB, Kang YJ (2000) Metallothionein inhibits peroxynitriteinduced DNA and lipoprotein damage. J Biol Chem 275:38957-38960
26. Shimoda R, Achanzar WE, Qu W et al (2003) Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 73:294-300
27. Kim HG, Kim JY, Han EH et al (2011) Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett 585:421-428
28. Seibold P, Hein R, Schmezer P et al (2011) Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int J Cancer 129:1467-1476